Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants

Inclusion Criteria: Inclusion criteria for adult subjects : * Healthy adults aged 18-49 days; * Proven legal identification; * The subject can understand and voluntarily sign the informed consent form. Inclusion criteria for children subjects : * Healthy children aged 4 years old; * Subjects who have completed primary immunization with 3 doses of sIPV vaccine; * Proven legal identification and vaccination certificate; * The subject and/or guardian can understand and voluntarily sign the informed consent form. Inclusion criteria for infant subjects: * Healthy infants aged 2 months (60\~89 days) * Proven legal identification and vaccination certificate; * The subject and/or guardian can understand and voluntarily sign the informed consent form. Exclusion Criteria: Exclusion criteria for adult subjects: * Women aged 18 to 49 years, positive urine pregnancy test, pregnant women, breastfeeding women, or planning to become pregnant within 3 months; * Previous history of vaccination of sIPV vaccine; * Allergy history, history of asthma, including allergy history to vaccine or vaccine components, serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioneurotic edema or stomachache, etc; * Congenital malformation or developmental disorder, genetic defect, serious malnutrition, etc.; * Autoimmune disease or immunodeficiency/immunosuppression; * Thyroid disease or thyroidectomy history, absence of spleen, functional absence of spleen, and any conditions resulting in absence of spleen or splenectomy; * Serious chronic diseases, serious cardiovascular diseases, hypertension that cannot be controlled by drugs (systolic blood pressure \> 140mmHg, diastolic blood pressure \> 90mmHg), diabetes, liver and kidney diseases, malignant tumors, etc; * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * Medical diagnosis of coagulation abnormalities (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or marked bruising or coagulation disorders; * Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; * History of alcohol or drug abuse; * Receipt of blood products within in the past 3 months; * Receipt of other investigational drugs in the past 30 days; * Receipt of attenuated live vaccines in the past 14 days; * Receipt of inactivated or subunit vaccines in the past 7 days; * Acute diseases or acute exacerbation of chronic diseases in the past 7 days; * Axillary temperature \>37.0°C; * According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial. Exclusion criteria for children subjects: * Have received 4 doses of sIPV vaccine; * History of polio; * Allergy history, history of asthma, including allergy history to vaccine or vaccine components, serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioneurotic edema or stomachache, etc; * Congenital malformation or developmental disorder, genetic defect, serious malnutrition, etc.; * Autoimmune disease or immunodeficiency/immunosuppression; * Thyroid disease or thyroidectomy history, absence of spleen, functional absence of spleen, and any conditions resulting in absence of spleen or splenectomy; * Suffering from serious cardiovascular diseases, diabetes, liver and kidney diseases, malignant tumors, etc; * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * Medical diagnosis of coagulation abnormalities (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or marked bruising or coagulation disorders; * Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; * History of alcohol or drug abuse; * Receipt of blood products within in the past 3 months; * Receipt of other investigational drugs in the past 30 days; * Receipt of attenuated live vaccines in the past 14 days; * Receipt of inactivated or subunit vaccines in the past 7 days; * Acute diseases or acute exacerbation of chronic diseases in the past 7 days; * Axillary temperature \>37.0°C; * According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial. Exclusion criteria for infant subjects: * Previous history of vaccination of sIPV vaccine; * History of polio; * Allergy history, history of asthma, including allergy history to vaccine or vaccine components, serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioneurotic edema or stomachache, etc; * Preterm birth babies (delivered before 37 weeks gestation), low birth weight (girls with birth weight \<2300g, boy with birth weight\<2500 g); * History of dystocia, asphyxia and nervous system damage at birth; * Congenital malformation or developmental disorder, genetic defect, serious malnutrition, etc.; * Autoimmune disease or immunodeficiency/immunosuppression; * Thyroid disease or thyroidectomy history, absence of spleen, functional absence of spleen, and any conditions resulting in absence of spleen or splenectomy; * -Suffering from serious cardiovascular diseases, diabetes, liver and kidney diseases, malignant tumors, etc; * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * Medical diagnosis of coagulation abnormalities (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or marked bruising or coagulation disorders; * Have received immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy); * Receipt of blood products ; * Receipt of other investigational drugs in the past 30 days; * Receipt of attenuated live vaccines in the past 14 days; * Receipt of inactivated or subunit vaccines in the past 7 days; * Acute diseases or acute exacerbation of chronic diseases in the past 7 days; * Axillary temperature \>37.0°C; * According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.